Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-503"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"lt"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-503"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5042
lpv:speaker	lp:Radvilė Morkūnaitė-mikulėnienė2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 member; Delegation for relations with the United States (2009-09-16--2014-06-30)3 member; ENVI (2009-07-16--2012-01-18)3 substitute; REGI (2009-07-16--2012-01-18)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 unknown; Tėvynės sąjunga - Lietuvos krikščionys demokratai (2009-07-14--2014-06-30)3
lpv:translated text	"In my opinion, the two most important elements of this whole document are the inclusion of the patient in the information system and the fact that all information, reliable information, will be accessible in one place. These figures are truly appalling – approximately 200 000 deaths a year from the side effects of drugs. Another issue is the fact that the recording of cases of side effects is very uneven throughout the Member States. Let us say that in my country, there are around 170 cases, but in other countries, there are at least several times that amount. The reason for this is that the patients were not directly involved in providing information. Doctors are often afraid to report relevant information, perhaps fearing that they may be accused of improper conduct. I am especially pleased that patients concerned about their health will be able to inform national institutions of the negative side effects of medicines. Another thing is to urge institutions in the European Union Member States to be more active in their response to relevant reports. The situation at present is such that around half of the Member States are slow to provide information about side effects. It is excellent that henceforth, manufacturers, consumers and control institutions will all be included in the medicine safety control system. A common position is required, based on responsibility, not fear."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph